Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lax

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Dalton Transactions (Cambridge, England : 2003)|December 22, 2009
On the many roles of NH3 ligands in mono- and multinuclear complexes of platinumPablo J Sanz Miguel, Michael Roitzsch, Lu Yin, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Dalton Transactions (Cambridge, England : 2003)|December 22, 2009
On the many roles of NH3 ligands in mono- and multinuclear complexes of platinumPablo J Sanz Miguel, Michael Roitzsch, Lu Yin, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Pageof 4